Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc (NQ: OVID )

1.036 +0.006 (+0.63%)
Streaming Delayed Price Updated: 11:15 AM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ovid Therapeutics Inc

< Previous 1 2 Next >
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 94 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 149 companies reached new 52-week lows. 
Via Benzinga
Ovid Therapeutics: Q1 Earnings Insights
Ovid Therapeutics (NASDAQ:OVID) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
3 Biotech Stocks Under $10 to Add to Your Buy List
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. 
Via InvestorPlace
Overview Of Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock increased by 28.7% to $2.24 during Thursday's pre-market session. The company's market cap stands at $31.4... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're starting off the day with an overview of the biggest pre-market stock movers to watch on Thursday! 
Via InvestorPlace
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small... 
Via Benzinga
5 Value Stocks In The Healthcare Sector
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Aytu BioPharma (NASDAQ:AYTU) stock increased by 19.36% to $6.41 during Tuesday's pre-market session. The market value of their outstanding shares is at $161.3... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Bionano Genomics (NASDAQ:BNGO) st... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021
Upgrades Compass Point upgraded the previous rating for Newtek Business Services Corp (NASDAQ:NEWT) from Neutral to Buy. For the fourth quarter, Newtek Business Services... 
Via Benzinga
Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions
Ovid Therapeutics Inc (NASDAQ: OVID) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.